Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Go back to Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Werewolf Therapeutics, Inc. (HOWL) Tops Q2 EPS by 7c

August 14, 2025 7:24 AM EDT

Werewolf Therapeutics, Inc. (NASDAQ: HOWL) reported Q2 EPS of ($0.40), $0.07 better than the analyst estimate of ($0.47).

For earnings history and earnings-related data on Werewolf Therapeutics, Inc. (HOWL) click here.

... More